ATE364048T1 - Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität - Google Patents

Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität

Info

Publication number
ATE364048T1
ATE364048T1 AT04011673T AT04011673T ATE364048T1 AT E364048 T1 ATE364048 T1 AT E364048T1 AT 04011673 T AT04011673 T AT 04011673T AT 04011673 T AT04011673 T AT 04011673T AT E364048 T1 ATE364048 T1 AT E364048T1
Authority
AT
Austria
Prior art keywords
cea
peptides
carcinoembryonic antigen
antagonistic activity
tachykinin antagonistic
Prior art date
Application number
AT04011673T
Other languages
English (en)
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE364048T1 publication Critical patent/ATE364048T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04011673T 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität ATE364048T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
ATE364048T1 true ATE364048T1 (de) 2007-06-15

Family

ID=22036775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
AT04011673T ATE364048T1 (de) 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Country Status (11)

Country Link
EP (1) EP1017810B1 (de)
JP (1) JP4291508B2 (de)
AT (2) ATE267213T1 (de)
AU (1) AU745863B2 (de)
CA (1) CA2308127C (de)
CY (1) CY1107706T1 (de)
DE (2) DE69837896T2 (de)
DK (1) DK1447414T3 (de)
ES (2) ES2217585T3 (de)
PT (1) PT1447414E (de)
WO (1) WO1999019478A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
EP2169073B1 (de) * 1999-10-11 2013-11-13 Institut Pasteur Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
AU1013601A (en) * 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
JP2004524004A (ja) * 2000-07-31 2004-08-12 アヴェンティス パストゥール リミテッド 修飾ｃｅａおよびその使用
AU2003203140A1 (en) * 2002-01-17 2003-07-30 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
WO2004050855A2 (en) * 2002-12-04 2004-06-17 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
KR101241272B1 (ko) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
WO2005114444A1 (en) 2004-04-30 2005-12-01 America Online, Inc. Network configuration management
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
BRPI0814140A2 (pt) 2007-07-27 2017-03-28 Immatics Biotechnologies Gmbh composição de peptídeos associados a tumor e vacina anticâncer relacionada
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP3320915A1 (de) 2009-04-17 2018-05-16 Globeimmune, Inc. Kombinationsimmuntherapiezusammensetzungen gegen krebs sowie verfahren
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
KR20170102002A (ko) 2015-01-09 2017-09-06 이투빅스 코포레이션 에볼라 바이러스 백신접종을 위한 방법 및 조성물
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102623C (en) * 1991-05-06 2003-04-22 Jeffrey Schlom Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
EP1017810A1 (de) 2000-07-12
PT1447414E (pt) 2007-07-18
CA2308127A1 (en) 1999-04-22
ES2217585T3 (es) 2004-11-01
ES2286530T3 (es) 2007-12-01
AU745863B2 (en) 2002-04-11
JP4291508B2 (ja) 2009-07-08
AU9500498A (en) 1999-05-03
WO1999019478A1 (en) 1999-04-22
JP2002500002A (ja) 2002-01-08
DE69837896D1 (de) 2007-07-19
DE69824023D1 (de) 2004-06-24
CY1107706T1 (el) 2013-04-18
ATE267213T1 (de) 2004-06-15
DK1447414T3 (da) 2007-09-10
CA2308127C (en) 2011-03-22
DE69837896T2 (de) 2008-02-14
DE69824023T2 (de) 2005-05-12
EP1017810B1 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
EA199800946A1 (ru) Концентрированный препарат антител
TR200003843T2 (tr) HCV kaplama proteinlerinin parçacıkları: aşılama için kullanım
DK0662000T3 (da) Antigen-bærende mikropartikler og deres anvendelse til at inducere humorale eller cellulære responser
ATE286907T1 (de) Cytokinin-designiertes lerk-5
DE69514342D1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
DK0669929T3 (da) Elk-ligand, et cytokin
DE3485229D1 (de) Shampoo-praeparate.
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
ATE247484T1 (de) Von der telomerase abgeleitete antigene peptide
DK0871702T3 (da) Cytokin betegnet Lerk-7
EP0695171A1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ES2140489T3 (es) Receptor de interferona soluble, su preparacion y su uso.
HU9300900D0 (en) Human gamma-interferon antagonists
DE69227898D1 (de) Rekombinante hybride porinepitope
DE69637078D1 (de) Polypeptid-fragmente die fähig sind mit dem antigen i/ii von streptococcus mutans zu konkurrieren
EP1447414A3 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
SE8502540D0 (sv) Stable dentifrice containing dextranase
DE59814002D1 (de) Sekretion von tragergebundenen proteinen in das periplasma und in den extrazellulären raum
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1447414

Country of ref document: EP